Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05998135
PHASE2

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Sponsor: Emory University

View on ClinicalTrials.gov

Summary

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Official title: Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2023-11-09

Completion Date

2027-06-30

Last Updated

2025-09-11

Healthy Volunteers

No

Interventions

DRUG

Atovaquone

Given PO

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Paracentesis

Undergo paracentesis

Locations (1)

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, United States